Navigation Links
Apexigen, Inc. Announces Collaboration for Antibody Discovery
Date:12/7/2010

BURLINGAME, Calif., Dec. 7, 2010 /PRNewswire/ -- Apexigen, Inc. announced today that it has entered into a collaboration and worldwide license agreement with Centocor Research & Development, Inc. and its affiliates to utilize Apexigen's proprietary therapeutic antibody technologies to discover and develop monoclonal antibody drugs.  Apexigen will generate and screen antibodies to several targets specified by Centocor R&D, which will be responsible for development and commercialization of all products resulting from the collaboration.  While financial details were not disclosed, Apexigen will receive an upfront license fee, and is eligible to receive future milestone and royalty payments if certain development and commercialization milestones are achieved.

Apexigen's antibody technologies produce a broad diversity of antibodies with high specificity, high affinity, and unique epitopes, and can successfully generate antibodies against challenging antigens where competing technologies fail. This enables the development of 'best-in-class' therapeutic antibodies.  

"We're excited about this collaboration and look forward to working closely with Centocor R&D," said Dr. Xiaodong Yang, President & CEO of Apexigen.  "Our goal is to become a world leader in the development of best-in-class therapeutic antibodies.  To achieve this goal, we plan to collaborate with partners while also developing our own product pipeline."

About Apexigen

Apexigen, Inc. is a biopharmaceutical company focused on the discovery and development of best-in-class therapeutic antibodies.  Apexigen has exclusive rights to the proprietary antibody technologies that were developed by Epitomics, Inc. for the development and commercialization of human therapeutics. In addition, Apexigen assumed development and commercialization responsibility for a pipeline of therapeutic product programs initiated by Epitomics.

Located in Burlingame, CA, Apexigen is actively developing its internal therapeutic product pipeline and seeking to form collaborative relationships with pharmaceutical and biotechnology companies for the discovery and development of pharmaceutical products based on its humanized rabbit monoclonal antibody technologies.  More information about Apexigen is available at www.apexigen.com.Contact Mark Nevins, Vice President, Business DevelopmentTel: 650-931-6236, ext. 502Email:  mnevins@apexigen.com
'/>"/>

SOURCE Apexigen, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stryker Announces Definitive Agreement to Sell OP-1 for Use in Orthopaedic Bone Applications to Olympus
2. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
3. China Medical Technologies, Inc. Announces the Closing of US$150 Million Convertible Senior Note Offering and the Completion of Repurchase of US$105.9 Million Convertible Notes Due 2011
4. ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering
5. China Medical Technologies Announces its Subsidiaries, GP Medical and Beijing Yuande, Ranked 12th and 415th, respectively, in Deloitte Technology Fast 500 Asia Pacific 2010 Program
6. Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
7. Dendreon Announces Presentation of PROVENGE Data at the American Society of Hematology and the Society of Urologic Oncology Annual Meetings
8. HemaQuest Announces Appointment of New Executive Management Team; Company Establishes Headquarters in San Diego
9. Ascension Orthopedics Announces Implantation of the TITAN™ Modular Total Shoulder
10. Spherix Announces Post-Hoc Analysis of Phase 3 Trial With D-Tagatose in Diabetes
11. Curemark Announces Four New Sites Participating in Autism Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
Breaking Medicine News(10 mins):